DNA Stock Recent News

STONY BROOK, NY / ACCESSWIRE / June 13, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that the New York State Department of Health ("NYSDOH") approved the Company's TR8™ PGx ("TR8") pharmacogenomic (PGx) testing service. The Company is currently in discussions to provide large-scale testing to enterprise customers, healthcare networks, and concierge physicians seeking to add PGx testing to their test menu.

35 new wet-lab tested digital PCR Microbial DNA Detection Assays on research platform GeneGlobe target a wide range of pathogens causing tropical diseases, sexually transmitted and urine tract infections // QIAcuity digital PCR technology enables precise and sensitive detection of pathogens, supporting infectious disease research and public health efforts // New assays add to QIAGEN's comprehensive portfolio for microbial research showcased at ASM Microbe conference from June 13-17 35 new wet-lab tested digital PCR Microbial DNA Detection Assays on research platform GeneGlobe target a wide range of pathogens causing tropical diseases, sexually transmitted and urine tract infections // QIAcuity digital PCR technology enables precise and sensitive detection of pathogens, supporting infectious disease research and public health efforts // New assays add to QIAGEN's comprehensive portfolio for microbial research showcased at ASM Microbe conference from June 13-17

Ginkgo Bioworks (DNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Patent covers the Composition of the Company's Proprietary Linea™ RNAP, a Core Technology Empowering the Linea™ IVT Platform Patent Application Also Currently Pending in Key International Markets STONY BROOK, NY / ACCESSWIRE / June 5, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, announced today that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application 18/302,247, entitled "Compositions and Methods for RNA Synthesis." The resulting patent will cover the composition of the Company's chemically modified RNA polymerase enzyme branded Linea™ RNAP, with expected patent protection into 2041.

Ginkgo is embarking on a cost-cutting plan that could pave the path to profitability and share performance. The main bear case against Ginkgo is there's no compelling reason to buy the stock right now.

Ginkgo Bioworks is still struggling with operating efficiency. Management is signaling that its processes may be streamlined.

QIAseq Multimodal DNA/RNA Lib Kit enables streamlined DNA and RNA library preparation for next-generation sequencing from a single sample // New kit advances precision medicine by facilitating multiomic studies and Comprehensive Genomic Profiling, crucial for understanding complex diseases like cancer // Researchers are provided with the first multimodal sequencing kit for multiple sample types, offering high flexibility and sensitivity, saving sample material and time QIAseq Multimodal DNA/RNA Lib Kit enables streamlined DNA and RNA library preparation for next-generation sequencing from a single sample // New kit advances precision medicine by facilitating multiomic studies and Comprehensive Genomic Profiling, crucial for understanding complex diseases like cancer // Researchers are provided with the first multimodal sequencing kit for multiple sample types, offering high flexibility and sensitivity, saving sample material and time

Cathie Wood likes to invest in risky biotech stocks. Ginkgo Bioworks has ambitions to disrupt biopharma manufacturing.

Ginkgo Bioworks is using a unique approach to laboratory automation. It's also spending a lot of its finite supply of money on this endeavor.

Shares of Ginkgo Bioworks have been beaten severely in response to heavy financial losses. The company's cell foundry could disrupt the biopharmaceutical manufacturing industry.